Cargando…
Experience with dose escalation using CHARTWEL (continuous hyperfractionated accelerated radiotherapy weekend less) in non-small-cell lung cancer.
Results from the multicentre randomized trial of CHART (continuous, hyperfractionated, accelerated radiotherapy) in non-small-cell lung cancer (NSCLC) showed a significant increase in survival (P=0.004) compared with conventional radiotherapy and a therapeutic benefit relative to late radiation-indu...
Autores principales: | Saunders, M. I., Rojas, A., Lyn, B. E., Pigott, K., Powell, M., Goodchild, K., Hoskin, P. J., Phillips, H., Verma, N. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group|1
1998
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063173/ https://www.ncbi.nlm.nih.gov/pubmed/9823973 |
Ejemplares similares
-
Continuous, hyperfractionated, accelerated radiotherapy (CHART).
por: Dische, S., et al.
Publicado: (1989) -
Non-small cell lung cancer and CHART (continuous hyperfractionated accelerated radiotherapy)--where do we stand?
por: Eakin, R. L., et al.
Publicado: (2000) -
Carbogen and nicotinamide in the treatment of bladder cancer with radical radiotherapy.
por: Hoskin, P. J., et al.
Publicado: (1997) -
Failure-specific prognostic factors after continuous hyperfractionated accelerated radiotherapy (CHART) or conventional radiotherapy in locally advanced non-small-cell lung cancer: A competing risks analysis
por: Ataman, Ö U, et al.
Publicado: (2001) -
Hyperfractionated radiotherapy for re-irradiation of recurrent esophageal cancer
por: Takeda, Kazuya, et al.
Publicado: (2021)